Anderson J P, Johnson M A, O'Brien P Q. "Method for the Synthesis of Dabigatran Impurity 12" [P]. US Patent, US 10044362 B2, 2020-06-11.
参考文献 Literature
Garcia M, Rodriguez P. "Development and Validation of an LC-MS/MS Method for the Determination of 达比加群杂质12 in Pharmaceutical Formulations". Chromatographia, 2016, 2042, (7), 1832-1860.
Smith J A, Johnson M B. "A Stability-Indicating HPLC Method for the Separation and Quantification of 达比加群杂质12 as an Impurity". Talanta, 2018, 1793, 5550-5556.
Zhang Y, Li Q, Chen T. "Identification and Structural Characterization of a Novel Degradation Product of Dabigatran Impurity 12 Using HRMS and NMR". J. Nat. Prod., 2022, 774, (8), 4305-4318.
Martinez C, Lopez D R. "Forced Degradation Studies to Evaluate 达比加群杂质12 Profile in Drug Substances According to ICH Guidelines". Biomed. Chromatogr., 2020, 2317, 9456-9462.